CLADRIBINE

Course overview

MULTIPLE SCLEROSIS (MS) IS AN IMMUNE-MEDIATED INFLAMMATORY DEMYELINATING DISEASE OF THE CENTRAL NERVOUS SYSTEM, RESULTING IN LOSS OF OLIGODENDROCYTES, ASTROGLIAL SCARRING, AND AXONAL INJURY (END-STAGE). DISEASE-MODIFYING DRUGS HELP MINIMIZE LONG-TERM DISABILITY FOR PEOPLE WITH MS BY DECREASING CNS INFLAMMATION, REDUCE THE FREQUENCY AND SEVERITY OF ACUTE ATTACKS, DELAY DISEASE PROGRESSION, AND IMPROVE THE OVERALL QUALITY OF LIFE. THIS ACTIVITY COVERS CLADRIBINE, AN ESTABLISHED ORAL CHEMOTHERAPY AGENT THAT THE FDA RECENTLY APPROVED FOR RELAPSING MS.